SF-25 Colon adenocarcinoma antigen, and antibodies with recognize this antigen

• US 5,212,085 A
• Filed: 06/07/1988
• Issued: 05/18/1993
• Est. Priority Date: 12/09/1987
• Status: Expired due to Term

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Wands, Jack R., Takahashi, Hiroshi
• Primary Examiner(s): Lacey, David L.
• Assistant Examiner(s): Hutzell, Paula
• Application Number:
  US06/203,198
• Time in Patent Office: 1,806 Days
• Field of Search: 530/387, 530/388.85, 530/388.8, 530/389.7, 530/391.3, 530/387.7, 435/240.27, 435/172.2, 435/70.21
• US Class Current: 435/343
• CPC Class Codes: A61K 2123/00 Preparations for testing in vivo
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 51/1048 the tumor cell determinant being a carcino embryonic antigen
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/3046 Stomach, Intestines

Abstract

The present invention pertains to the SF-25 antigen of colon adenocarcinoma cells, to functional derivatives of this antigen, and to antibodies and antibody fragments capable of binding this antigen. The invention further discloses methods of diagnosing and treating colon cancer which employ the above molecules.

Claims

1. A molecule which specifically binds to the SF-25 antigen of a colon adenocarcinoma cell, said molecule being selected from the group consisting of:

(a) an antibody substantially free of natural contaminants;

(b) a monoclonal antibody;

(c) a fragment of (a) or (b).

2. The molecule of claim 1, wherein said molecule is said antibody substantially free of natural contaminants.

3. The molecule of claim 1, wherein said molecule is said monoclonal antibody.

4. The molecule of claim 1, wherein said molecule is said fragment of an antibody.

5. The molecule of claim 1, wherein said molecule is a fragment of said monoclonal antibody.

6. The molecule of claim 1, wherein said fragment is an F(ab)₂ fragment.

7. The molecule of claim 1, wherein said fragment is an F(ab) fragment.

8. The molecule of claim 1, wherein said molecule is labeled with a detectable moiety.

9. A hybridoma cell line which secretes a monoclonal antibody, said antibody specifically binding to the SF-25 antigen of a colon adenocarcinoma cell.

10. The hybridoma cell line of claim 9, which is ATCC strain HB 9599.

11. The monoclonal antibody obtainable from the hybridoma cell line of claim 9.

12. The monoclonal antibody obtainable from the hybridoma cell line of claim 10.